Anaphylaxis is a potentially fatal, immediate hypersensitivity reaction. Mast cells and basophils, by elaborating vasoactive mediators and cytokines, are the main primary e ector cells of anaphylaxis. Mast cells have been identi ed in human heart between myocardial bers, perivascularly, in the adventitia, and in the arterial intima. Mast cells isolated from human heart tissue (HHMC) of patients undergoing cardiac transplantation express high a nity immunglobulin E (IgE) receptors (FcεRI), C3a, C5a, and kit receptors (KIT). Anti-IgE, anti-FcεRI, and immunoglobulin superallergens induce in vitro secretion of preformed mediators (histamine, tryptase, chymase, and renin) and the de novo synthesis of cysteinyl leukotriene C 4 (LTC 4 ) and prostaglandin D 2 (PGD 2 ) from HHMC. Complement is activated and anaphylatoxin forms during anaphylaxis. C5a and C3a cause the in vitro release of histamine and tryptase from HHMC. erapeutic (general anesthetics, protamine, etc.) and diagnostic agents (radio contrast media, etc.), which can cause anaphylactoid reactions, activate HHMC in vitro. Low concentrations of histamine and cysteinyl leukotrienes given to subjects undergoing diagnostic catheterisation caused signi cant systemic and coronary hemodynamic e ects. ese data indicate that human heart mast cells and their mediators play a role in severe anaphylactic reactions.
Introduction
Anaphylaxis is the most dramatic and potentially fatal manifestation of immediate hypersensitivity, accounting for more than 500 deaths annually [1, 2] . Anaphylaxis is characterized by laryngeal edema, bronchoconstriction, hypotension, and vascular leakage. It is well known that the heart is directly and/or indirectly involved in severe human anaphylaxis [3, 4, 5, 6, 7, 8, 9] . Cardiac anaphylaxis in humans is characterized by coronary spasm, decreased le ventricular contractility, and/or arrhythmias [10, 11, 12, 13] . Myocardial lesions might be the anatomical basis for the irreversible cardiac failure occasionally associated with systemic anaphylaxis [14] .
Coronary spasm or myocardial infarction can occur a er insect stings [15, 16] and as a consequence of idiopathic anaphylaxis [17] . Moreover, patients with anaphylaxis may present profound myocardial depression presumably due to the negative inotropic e ects of mast cell-derived mediators [18] .
In this review we draw together evidence that cardiac mast cells and their mediators play a role in systemic and cardiac human anaphylaxis.
Mast cells are present in human heart
Several years ago Vincenzo Patella, in collaboration with Bärbel Lamparter-Schummert and Monika Adt, established in our laboratory an elegant technique to isolate and purify mast cells from heart tissue of patients undergoing heart transplantation [19, 20, 21] .
Mast cells are present in normal and atherosclerotic human intima of coronary arteries [12, 13, 22, 23, 24] . We have identi ed and characterized mast cells around coronary blood vessels and between myocardial bers by electron microscopy in all sections of human hearts [19, 20, 25] . Tab. 1 summarizes the three di erent localizations of mast cells in human cardiac tissue we have found examining sections of more than 50 hearts [19, 20] . A small percentage (about 5 %) of cardiac mast cells appears partially degranulated [23, 19] . Fig. 1 shows the electron micrograph of a human cardiac mast cell in close contact with the capillary vessel wall. e presence of mast cells close to coronary vessels suggests that circulating antigens, superallergens, autoantibodies (anti-IgE, anti-FcεRI, etc.), complement (C3a and C5a), drugs (general anesthetics, protamine, etc.), and diagnostic agents (radio contrast media, etc.) can easily reach perivascular HHMC. Activated mast cells can in turn release vasoactive substances (histamine, cysteinyl leukotrienes, PGD 2 , platelet-activating factor; PAF, etc.) that can a ect blood vessels [26] .
Cardiac mast cell density and the histamine and tryptase contents of mast cells isolated from failing hearts from patients with idiopathic dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) undergoing heart transplantation were higher than in control hearts (CH) without cardiovascular disease [27] . Immunologic activation of HHMC induced a signi cantly greater release of mediators (histamine, tryptase, and LTC 4 ) in patients with failing hearts than in CH. e latter observation suggests that underlying cardiovascular diseases might represent a risk factor for severe anaphylaxis.
Mediators synthesized by HHMC
HHMC contain histamine (≈ 3 pg/cell), tryptase (≈ 24 µg/10 6 cells) and IgE-mediated activation of HHMC caused tryptase release parallel to histamine secretion [19] . By using the immunogold technique we showed that HHMC contain chymase as well as tryptase [19] . Human chymase generates angiotensin II from angiotensin I, acting as an angiotensin-converting enzyme [28] . Interestingly, supernatants of HHMC challenged in vitro with anti-IgE can convert angiotensin I into angiotensin II, suggesting that chymase released from HHMC play a role in the homeostatic control of blood pressure.
erefore, the activation of HHMC and release of chymase may control blood pressure during anaphylaxis. Review Article Human heart as a shock organ in anaphylaxis
We have extended the seminal observation by Roberto Levi´s and Randi B. Silver's groups [29, 30] by demonstrating that HHMC also contain renin [Marone G., unpublished information] . us, there is the possibility that renin released from activated cardiac mast cells can trigger local formation of angiotensin II.
Activation of HHMC with anti-IgE or anti-FcεRI induces the de novo synthesis of PGD 2 (≈ 18 ng/10 6 cells) and LTC 4 (≈ 18 ng/10 6 cells) [19, 20] . is is a relevant observation because both PGD 2 and LTC 4 have several cardiovascular e ects [31, 32] , meaning that the release of PGD 2 from HHMC can cause coronary vasoconstriction in man.
PAF is an important mediator of anaphylaxis produced by human mast cells [33] . ere is preliminary evidence that immunologically activated HHMC synthesize PAF (Triggiani M., unpublished information). Importantly, serum PAF levels are directly correlated and PAF acetylhydrolase levels are inversely correlated with the severity of anaphylaxis [34] . Fig. 2 summarizes the principal receptors present on the surface of HHMC and the mediators released by their activation.
Cytokines synthesized by HHMC
Cytokines have been implicated in the pathogenesis of a variety of cardiovascular diseases [35] . ere is growing evidence of the possible roles of cardiac mast cell-derived cytokines in anaphylaxis. Mast cells in human coronary atheromas contain TNF-α [36] . We have demonstrated the presence of granule-associated stem cell factor (SCF), the principal growth factor for human mast cells [37] , in HHMC of patients with dilated cardiomyopathy [27] . us, there is the possibility that SCF released by HHMC is an autocrine factor that contributes to mast cell hyperplasia observed in dilated cardiomyopathy [27] . Additional studies are necessary to clarify the roles of other cytokines in anaphylaxis and the contribution of cardiac mast cells to their production.
Stimuli that activate HHMC in vitro
Immunologic activation of HHMC can be induced by IgE-mediated stimuli (antigens, immunoglobulin superantigens, anti-IgE or anti-FcεRI) [19, 20, 38, 39] . Activation of HHMC by anti-IgE and by a monoclonal antibody against an epitope of the α-chain of FcεRI may be clinically important. Histamine-releasing autoantibodies against IgE or against the α-subunit of FcεRI are present in the circulation of some patients with various allergic disorders [40, 41] .
Anaphylatoxins (C3a and C5a) are formed when complement is activated during cardiac [42] and systemic anaphylaxis [9] . C5a causes cardiovascular derangement directly or through the release of vasoactive mediators [43, 44] . We demonstrated that C5a and C3a cause rapid histamine release from HHMC [19] . Interestingly, C3a causes cardiac dysfunction in the Langendor -perfused guinea pig heart system [44] . SCF, which is present in the secretory granules of HHMC [27] and is released a er their immunologic activation [45] , activates HHMC through the engagement of kit receptor. Eosinophil granule proteins (ECP and MBP) are selective activators of HHMC [20, 46, 47] . e latter observation suggests that eosinophil-mast cell interactions might be clinically relevant in patients with hypereosinophilia.
A variety of non-immunological stimuli can activate HHMC. Some of clinical relevance because they might explain adverse e ects observed in vivo when these compounds are used for diagnostic (contrast media, etc.) [3, 7] or therapeutic purposes (general anesthetics, protamine, etc.) [20] . For example, protamine and certain general anesthetics (propofol and atracurium) can cause histamine release from HHMC [20, 48] . Radio contrast media, injected into the coronary arteries for diagnostic purposes, can also activate HHMC in vitro [20] . e proximity of HHMC to coronary blood vessels [12, 13] and the presence of mast cells in human coronary atheromas [23] suggest that intracoronary injection of high doses of contrast media can activate mast cells and induce in vivo release of vasoactive mediators. In fact, in a multicenter study of patients who experienced immediate reactions to the injection of contrast media, the concentrations of plasma histamine and tryptase rose [49] .
HHMC in systemic and cardiac anaphylaxis
Roberto Levi's group has provided extensive evidence that the heart is involved in experimental anaphylaxis [29, 30, 43, 50] through the release of chemical mediators from cardiac mast cells. ere is increasing evidence of cardiac involvement in human anaphylaxis too [8, 9, 12, 13] . Initially this has been attributed to mediators originating from the lung and reaching the heart. However, it is likely that the local release of vasoactive mediators by mast cells around coronary arteries and in human coronary atheromas, particularly in patients with ischemic heart disease [23] , can contribute to cardiovascular derangements during anaphylaxis. In addition, C5a formation has been documented during anaphylaxis in man [9] . HHMC possess FcεRI, C3a receptor (C3aR), and C5a receptor (C5aR) bound to their membrane surface. erefore, it is likely that IgE-, C5a-, and C3a-mediated activation of these cells could play a role in systemic and cardiac anaphylaxis in humans [9, 12, 13] .
In addition, several agents injected intravenously (general anesthetics, protamine, radio contrast me-dia, etc.) can cause non-IgE-mediated anaphylactic reactions in vitro [20, 48] and in vivo [49] . erefore, the release of mediators caused by these agents from cardiac mast cells may well be involved in anaphylactic reactions related to these compounds.
Cardiovascular e ects of histamine in man
Several years ago, in collaboration with our colleagues of the Division of Cardiology at the University of Naples Federico II, we have investigated the e ects of histamine on peripheral and coronary hemodynamics in man. Low doses of histamine (0.4 µg/kg/min) infused in patients with normal le ventricular (LV) function undergoing diagnostic catheterisation induced signi cant drops in systolic, diastolic, and mean aortic pressure, systemic vascular resistance, LV end-diastolic pressure, and stroke index [51] . Hemodynamic changes started 1-2 min a er the infusion started and reverted to normal within 5 min a er the infusion. In one subject there was a transient progression from rst to third degree atrioventricular block, with prompt recovery of atrioventricular conduction at the end of the infusion. us, exogenous histamine in man causes signi cant transient hemodynamic changes, mainly systemic hypotension, tachycardia, and increased LV performance. ese changes can be partly attributed to the related increase in sympathoadrenergic activity, although it cannot be excluded that histamine has some direct cardiac e ect.
In a subsequent study, the e ects of selective activation of histamine H 1 receptors on coronary hemodynamics were examined in two groups: patients with atypical chest pain and normal coronary arteries and patients with vasospastic angina [52, 53] . H 1 receptor stimulation was achieved by infusing histamine intravenously for 5 min a er pretreatment with cimetidine to antagonize the H 2 receptors. Heart rate was kept constant by coronary sinus pacing. In the rst group mean aortic pressure and coronary vascular resistance (CVR) dropped, while coronary blood ow (CBF) and myocardial oxygen consumption remained unchanged during histamine infusion. No patient in this group developed angina during histamine infusion. By contrast, a percentage of the second group developed angina during histamine infusion (≈40 %), with a decrease in CBF and an increase in CVR. ese ndings suggest that stimulation of the H 1 receptor in subjects with normal coronary arteries reduces CVR, probably because of vasodilation of small coronary resistance vessels. However, in some patients with vasospastic angina, H 1 receptor activation can cause vasoconstriction of large-capacitance coronary arteries.
e results of these studies support the hypothesis that the endogenous release of histamine during anaphylactic reactions may precipitate coronary spasm in a subset of patients with vasospastic angina. Interestingly, it has been reported that premedication with an H 2 receptor antagonist increases the risk of heart block in patients who develop anaphylaxis [54] .
Studies have now started to clarify the role of H 3 receptors in the cardiovascular system. Roberto Levi and collaborators have identi ed H 3 receptors as inhibitory heteroreceptors in cardiac adrenergic nerve endings [55, 56] suggesting a mechanism by which endogenous histamine can activate norepinephrine release in normal and ischemic conditions [57] . e presence of H 3 receptors in human heart [55] suggests that these receptors might be directly and/or indirectly involved in anaphylactic reactions.
Cardiovascular e ects of cysteinyl leukotrienes in man
In collaboration with cardiologists we have evaluated the e ects of cysteinyl leukotriene D 4 (LTD 4 ) on systemic and coronary hemodynamic in patients with normal coronary arteries [17] . LTD 4 induced an early (20 s) transient fall in mean arterial pressure paralleled by rises in heart rate and plasma levels of catecholamines which returned to baseline a er 10 min. CVR rose at 10 and 15 min. us, small doses of cysteinyl leukotrienes may induce both an early transient fall in mean arterial pressure, with secondary sympatho-adrenergic activation, and a HHMC ,human cardiac mast cells; C3aR, C3a receptor; C5aR, C5a receptor; IgE, immunoglobulin E; SCF, stem cell factor; TNF-α, tumornecrosis factor α; KIT, tyrosine kinase receptor; PGD2, prostaglandine 2; LTC4, cysteinyl leukotriene C4; PAF, platelet-activating factor Review Article Human heart as a shock organ in anaphylaxis later increase in small coronary arteriolar resistance. Although high levels of cysteinyl leukotriene receptor CysLT 2 mRNA were detected in the human heart and coronary artery, while cysteinyl leukotriene receptor CysLT 1 mRNA was barely detectable [58] , it is not clear which receptor was involved in these cardiovascular e ects.
Conclusion
Within human cardiac tissue, mast cells are located between myocytes and are in close contact with blood vessels [12, 13, 19, 20, 22, 45] . ey are also found in the coronary adventitia and in the shoulder regions of coronary atheroma [22, 23, 24] .
Circulating antigens, superantigens, autoantibodies (anti-IgE, anti-FcεRI, etc.), eosinophil granule proteins (major basic protein, MBP, and eosinophil cationic protein ECP), therapeutic (e. g. protamine, general anesthetics) or diagnostic substances (e. g. radio-contrast media) can induce the release of mediators from HHMC. ese cells express FcεRI, C5aR, and C3aR, which could explain the involvement of cardiac mast cells in systemic and cardiac anaphylaxis.
e increases in cardiac mast cell density and release of vasoactive mediators in patients with cardiomyopathy might also have clinical implications given the marked cardiovascular e ects of histamine, cysteinyl leukotrienes, and PGD 2 [31, 32, 51, 52, 53] .
Pioneering studies have started to shed light on the cardiovascular e ects in humans caused by such mast cell-derived mediators as histamine [51, 52, 53] and leukotrienes [12] . Interestingly, these studies provided the important information that the hemodynamic e ects of mediators depend on both the underlying cardiovascular conditions and pharmacologic treatment (e. g., H 2 blockade). Using speci c antagonists of CysLT 1 and CysLT 2 [58] it will be possible to assess the each receptor's contribution to the cardiovascular e ects of these vasoactive mediators. Immunologically activated human mast cells synthesize PAF [33] , which can play a role in human [34] and experimental anaphylaxis [59] .
In conclusion, there is extensive experimental and clinical evidence that the human heart can be viewed as both a site and a target in anaphylaxis. Pharmacological targeting of cardiac mast cells might o er novel therapeutic opportunities to prevent and/or modulate the dramatic and potentially fatal manifestations of anaphylaxis.
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